# Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

> **NCT01651767** · PHASE1 · TERMINATED · sponsor: **Janssen R&D Ireland** · enrollment: 11 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-47910382

## Key facts

- **NCT ID:** NCT01651767
- **Lead sponsor:** Janssen R&D Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Because of many competing trials using the same mechanism of action, but being further advanced in development
- **Last updated:** 2014-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01651767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01651767, "Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01651767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*